Drug Trial Radar · NCT00654576
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Apr 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,400
Planned (sponsor's estimate)
Start
Feb 2005
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Mental Health Center; Sichuan University; Capital Medical University; Nanjing Medical University; Jiangxi Mental Hospital; Hunan Mental Hospital; Guangzhou Mental Hospital; Chongqing Metal Institute; Henan Mental Hospital
- First posted
- Apr 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention. We hypothesize that there will be significant difference in the overall effectiveness between antipsychotic and antipsychotic combination with psychosocial intervention.
Conditions
- Schizophrenia
Interventions
Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, AripitrazoleDrug
patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
psychosocial interventionBehavioral
the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the time to discontinued treatment and the rate of relapse/rehospitalization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Mental Health of The Second Xiangya Hospital, Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.